The specific price of bimetinib/bemetinib

Binimetinib is a new generation of oral MEK inhibitors. It is mainly used to treat patients with BRAF V600 mutated melanoma and non-small cell lung cancer (NSCLC). Currently, the original drug has not been marketed in China and has not been included in the medical insurance catalog. Therefore, domestic patients can only obtain the drug through overseas channels, and the price details are relatively opaque. In the European market, the common specifications of bimetinib’s original drug are 15 mg 84 tablets and 15 mg 168 tablets. The price per box may exceed RMB 10,000, and the price will be adjusted due to exchange rate fluctuations. This limits the clinical accessibility of the drug, especially for patients who require long-term maintenance treatment, which imposes a high economic burden.

In order to improve drug accessibility, generic drugs with similar ingredients to the original drugs have appeared in overseas markets. For example, Bimetinib15mg*180 tablets produced by Laos Lucius Pharmaceutical Factory sells for about more than 6,000 yuan per box, which is significantly lower than the original drug. Although generic drugs are more advantageous in terms of price, they still need to follow the guidance of doctors when using them clinically to ensure that the efficacy and safety of the drugs are not affected. In addition, generic drugs in some countries and regions also provide patients with a variety of specifications to choose from, making it easier to flexibly adjust the medication plan according to individual dosage needs.

Taken together, the original drug Bimetinib is more expensive, but with its precise targeting effect and clinical efficacy, it has obvious value in the treatment ofBRAF V600 mutated melanoma and non-small cell lung cancer. The emergence of generic drugs not only improves economic accessibility, but also enables more patients to benefit from MEK inhibitor treatment. When choosing drugs, patients should reasonably arrange their medication plan based on their own financial situation, disease type and doctor's recommendations to obtain the best treatment effect and balance the financial burden.

Reference materials:https://go.drugbank.com/drugs/DB11967